(Q38009044)

26 August 2017

Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk (English)

1 reference

chronic renal insufficiency

26 August 2017

1 reference

Vlado Perkovic

6

0 references

Sunil Badve

object named as

Sunil V Badve

4

0 references

Carmel Hawley

object named as

Carmel M Hawley

5

0 references

Grahame Elder

7

object named as

Grahame J Elder

1 reference

26 August 2017

Nigel D Toussaint

1

1 reference

PubMed ID

22574672

26 August 2017

Eugenie Pedagogos

2

1 reference

PubMed ID

22574672

26 August 2017

Sven-Jean Tan

3

1 reference

26 August 2017

1 July 2012

1 reference

26 August 2017

1 reference

26 August 2017

17

1 reference

26 August 2017

5

1 reference

26 August 2017

433-444

1 reference

Relation between serum phosphate level and cardiovascular event rate in people with coronary disease

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum phosphate levels and mortality risk among people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Phosphatonins and the regulation of phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum phosphate and mortality in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Chronic kidney disease-mineral-bone disorder: a new paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum phosphorus levels associate with coronary atherosclerosis in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Association of serum phosphate with vascular and valvular calcification in moderate CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Elevated serum phosphate predicts mortality in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Dietary phosphorus acutely impairs endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

The emerging role of phosphate in vascular calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Arterial stiffness in chronic kidney disease: causes and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

The mechanism of phosphorus as a cardiovascular risk factor in CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Oral phosphate binders in patients with kidney failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Association of pretransplant serum phosphorus with posttransplant outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Cardiovascular risk factors in chronic kidney disease: does phosphate qualify?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Impact of aortic stiffness on survival in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Is lowering phosphate exposure the key to preventing arterial stiffening with age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

New strategy to attenuate pulse wave velocity in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Coronary artery calcification and mortality in diabetic patients with proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Phosphate regulation of vascular smooth muscle cell calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

The role of phosphorus in the development and progression of vascular calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Vascular calcification: in vitro evidence for the role of inorganic phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Relationship between circulating FGF23 and total body atherosclerosis in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

FGF23 induces left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Phosphorus binders and survival on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

A rat model of chronic kidney disease-mineral bone disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Forging forward with 10 burning questions on FGF23 in kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Relations of Serum Phosphorus and Calcium Levels to the Incidence of Cardiovascular Disease in the Community

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Association of Disorders in Mineral Metabolism with Progression of Chronic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Mortality in kidney disease patients treated with phosphate binders: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2012.01618.X

10.1111/J.1440-1797.2012.01618.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22574672